Updates and Advances in Multiple Sclerosis Neurotherapeutics
Neurodegenerative Disease Management · 2023-02 · 13 (1) · 47-70
DOI: 10.2217/nmt-2021-0058 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neurodegenerative Disease Management, online erschienen am 31.10.2022. Verfasst von Moein Amin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic, Department of Neurology, Cleveland, OH 44195, USA. Hauptthemen laut MEDLINE: Multiple Sclerosis, Hematopoietic Stem Cell Transplantation, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit wurde bisher 158-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS.
Abstract (Originalsprache)
The multiple sclerosis (MS) neurotherapeutic landscape is rapidly evolving. New disease-modifying therapies (DMTs) with improved efficacy and safety, in addition to an expanding pipeline of agents with novel mechanisms, provide more options for patients with MS. While treatment of MS neuroinflammation is well tailored in the existing DMT armamentarium, concerted efforts are currently underway for identifying neuropathological targets and drug discovery for progressive MS. There is also ongoing research to develop agents for remyelination and neuroprotection. Further insights are needed to guide DMT initiation and sequencing as well as to determine the role of autologous stem cell transplantation in relapsing and progressive MS. This review provides a summary of these updates. The range of treatment options available for multiple sclerosis (MS) is growing, with the aim of developing safer and more effective therapies. There are ongoing efforts to discover additional mechanisms of MS and create drugs that can target these pathways. A more tailored approach will allow better personalization of drug selection for patients. There is currently a special focus on identifying treatment targets for progressive MS, where there are only a limited number of therapeutic options available to date. In addition, there is ongoing research aimed at developing stem cell therapies, drugs that provide neuroprotection and agents that can potentially reverse the damage caused by MS through remyelination. In this review, these topics are summarized.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cleveland Clinic, Department of Neurology, Cleveland, OH 44195, USA.
- Cleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas, NV 89106, USA.
ORCID-Profile: Carrie M Hersh
Förderung
- NINDS NIH HHS
Zitieren
APA
Amin, M., & Hersh, C. M. (2023). Updates and Advances in Multiple Sclerosis Neurotherapeutics. Neurodegenerative Disease Management, 13(1), 47-70. https://doi.org/10.2217/nmt-2021-0058
Vancouver
Amin M, Hersh CM. Updates and Advances in Multiple Sclerosis Neurotherapeutics. Neurodegenerative Disease Management. 2023;13(1):47-70. doi:10.2217/nmt-2021-0058
BibTeX
@article{Amin2023,
author = {Amin, Moein and Hersh, Carrie M},
title = {Updates and Advances in Multiple Sclerosis Neurotherapeutics},
journal = {Neurodegenerative Disease Management},
year = {2023},
volume = {13},
number = {1},
pages = {47--70},
doi = {10.2217/nmt-2021-0058}
}
EUVIMED